Difference between revisions of "LINC00165"
Chunlei Yu (talk | contribs) |
Chunlei Yu (talk | contribs) |
||
Line 3: | Line 3: | ||
==Annotated Information== | ==Annotated Information== | ||
===Name=== | ===Name=== | ||
− | + | LINC00165: long intergenic non-protein coding RNA 165 (HGNC nomenclature) | |
− | + | "narcolepsy candidate-region 1 gene B", NLC1-B<ref name="ref1" /> | |
===Characteristics=== | ===Characteristics=== | ||
− | NLC1- | + | NLC1-B, encoded in NLC1 (a candidate region for susceptibility/resistance to human narcolepsy ), is on the reverse strand on chromsome 21q22.3 with positions 45238709-45239923<ref name="ref1" />. |
− | |||
It belongs to the category of "Intergenic" in lncRNA classification<ref name="ref1" />. | It belongs to the category of "Intergenic" in lncRNA classification<ref name="ref1" />. | ||
===Function=== | ===Function=== | ||
− | + | SNP rs13048981 is located 2,602 bp upstream of NLC1-B, which was not expressed in human brain, and its position, 4,164 bp upstream of NLC1-A, suggests that its association with narcolepsy resulted merely from the LD with rs13046884 and D21S0012m. Thus, it is unlikely that NLC1-B is a susceptibility/resistance gene for human narcolepsy<ref name="ref1" />. | |
− | |||
− | NLC1-A | ||
Line 23: | Line 20: | ||
===Expression=== | ===Expression=== | ||
− | + | ||
{| class='wikitable' style="text-align:center" | {| class='wikitable' style="text-align:center" | ||
Line 31: | Line 28: | ||
! | Reverse primer | ! | Reverse primer | ||
|- | |- | ||
− | | rowspan="1"|NLC1- | + | | rowspan="1"|NLC1-B |
− | | | 5'- | + | | | 5'-CCTCACAGCATCCCACATT-3' |
− | | | 5'- | + | | | 5'-TTTCTGGAAACAGCCAGGAG-3'<ref name="ref1" /> |
|} | |} | ||
Latest revision as of 14:30, 10 April 2015
LINC00163 encoded on the reverse strand of NLC1 on chromosome 21q22.3 play a role in human narcolepsy.
Contents
Annotated Information
Name
LINC00165: long intergenic non-protein coding RNA 165 (HGNC nomenclature)
"narcolepsy candidate-region 1 gene B", NLC1-B[1]
Characteristics
NLC1-B, encoded in NLC1 (a candidate region for susceptibility/resistance to human narcolepsy ), is on the reverse strand on chromsome 21q22.3 with positions 45238709-45239923[1].
It belongs to the category of "Intergenic" in lncRNA classification[1].
Function
SNP rs13048981 is located 2,602 bp upstream of NLC1-B, which was not expressed in human brain, and its position, 4,164 bp upstream of NLC1-A, suggests that its association with narcolepsy resulted merely from the LD with rs13046884 and D21S0012m. Thus, it is unlikely that NLC1-B is a susceptibility/resistance gene for human narcolepsy[1].
Diseases
- human narcolepsy
Expression
RT-PCR | Forward primer | Reverse primer |
---|---|---|
NLC1-B | 5'-CCTCACAGCATCCCACATT-3' | 5'-TTTCTGGAAACAGCCAGGAG-3'[1] |
Sequence
>gi|22800663|gb|BC009635.1| Homo sapiens chromosome 21 open reading frame 135, mRNA (cDNA clone IMAGE:3891427), with apparent retained intron
000081 GAGGGGCTGG CAGAGCCCCA GGCTCCAGTC CACACCCACC GGCCCCAGGT CTGGCCATGG GCTGGGCCCT GGTGTGCAGA 000160
000161 CAGCAGTGGC CACTGCTCCA GGGCCTTTGC ACCAGCCTGC TGCAGGTCCA GGCGGTCATG GGGAGTGGAG CCGCAGCGGC 000240
000241 CTCTTGTTTT CCTTCCCCTC TTGGGAGACG GCTGCTCCTC CTGGCTGTTT CCAGAAAGTG TGTTTGTTAT TTGGCTCCTG 000320
000321 GAAACACCAT CTGATGAAAC AGGCTCTGTT GGGCTGGCCT GCCAGGCGGA GGCTGTGGGC GCCCAGGAGT CTCACCACGA 000400
000401 AGCAGGTGGC AGAGGCCCGA TAGCCCCACC CTGCAGGCCG GGACCTGGCA CCTAAACGGG GAGATGGAAG AACATGGAAA 000480
000481 ATTCCCTAAG AGCAAATTGA TGCTCAGCTT CCGCGGGCAC CAACTTGCTG CGGAATCCTG CTTTGCAGAT CATCGTTCCT 000560
000561 CGAGCATTCG GACGCCTCGG GCCCCAGAAG TTCAAGAACA AGAAAGCTCT GTTTCATGCA GACACGCTCA CGCATGCACA 000640
000641 CATGCTCACA CATGCACTTA TACGTGCACA CACACACACA CACACAACAC ACACACACGC ACACTCACAC AACCATGGCC 000720
000721 ATGTAGCCCC AGTCTCAGCA TCATGTCCTC TATTTAGAAA TATTGGCTAA ACACCTAATA AATAACTAAA CAGAAATGTA 000800
000801 ATCTTTAATA AAGTCTCATA AACCAAAAAA AAAAAAAAA
Labs working on this lncRNA
- From the Departments of Sleep Disorder Research (Alfresa) (M.K.; T.E.) and Human Genetics (M.K.; H.H.; K.T.), Graduate School of Medicine, University of Tokyo, the Japanese Red Cross Central Blood Center (T.J.), and the Neuropsychiatric Research Institute (Y.H.), Tokyo; and the Department of Molecular Life Science, Tokai University School of Medicine, Kanagawa, Japan (G.T.; A.O.; H.I.) [1].